Global Neurological Biomarkers Market Report 2022 to 2028: Featuring Bio-Rad Laboratories, Merck, PerkinElmer and Shimadzu Among Others
21 mars 2023 11h33 HE
|
Research and Markets
Dublin, March 21, 2023 (GLOBE NEWSWIRE) -- The "Global Neurological Biomarkers Market Size, Share & Industry Trends Analysis Report by Type (Proteomic, Genomic, Metabolomic), Application...
Tiziana Life Sciences Highlighted in Forbes Article
17 mars 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, March 17, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Multiple Sclerosis Drugs Market Size is projected to reach USD 34.03 Billion by 2031, growing at a CAGR of 3.7%: Straits Research
08 mars 2023 08h30 HE
|
Straits Research
New York, United States, March 08, 2023 (GLOBE NEWSWIRE) -- Multiple sclerosis (MS) is an immune-mediated central nervous system disorder. Demyelination, inflammation, degenerative changes such as...
Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity
13 févr. 2023 07h00 HE
|
Clene Inc.
MRI results reinforce the clinical neurological improvements previously reportedMRI results showed improved brain neuronal structural integrity, independent of an immunomodulatory effectMRI results...
InvestmentPitch Media Video Discusses FSD Pharma’s Receipt of No Objection Letter from Health Canada for Clinical Trials for LUCID-21-302 for MS
09 févr. 2023 06h00 HE
|
InvestmentPitch Media and FSD Pharma
VANCOUVER, British Columbia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets...
InvestmentPitch Media Video Discusses FSD Pharma’s Submission of its Clinical Trial Application for Planned Phase-1 Trial for Lucid-MS, a Candidate for Treatment of MS
19 janv. 2023 06h00 HE
|
InvestmentPitch Media and FSD Pharma
VANCOUVER, British Columbia, Jan. 19, 2023 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets...
Outlook on the Myasthenia Gravis Diagnosis and Treatment Global Market to 2028 - Featuring Avadel Pharmaceuticals, Bausch Health Companies, Baxter International and CSL Behring Among Others
05 janv. 2023 06h58 HE
|
Research and Markets
Dublin, Jan. 05, 2023 (GLOBE NEWSWIRE) -- The "Global Myasthenia Gravis Diagnosis and Treatment Market Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering. The global...
AB Science a reçu l’approbation de la Food and Drug Administration (FDA) américaine pour initier l’étude confirmatoire de Phase 3 avec le masitinib dans le traitement des formes progressives de la sclérose en plaques
29 déc. 2022 12h09 HE
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE A RECU L’APPROBATION DE LA FOOD AND DRUG ADMINISTRATION (FDA) AMÉRICAINE POUR INITIER L’ÉTUDE CONFIRMATOIRE DE PHASE 3 AVEC LE MASITINIB DANS LE TRAITEMENT DES FORMES...
AB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the treatment of progressive multiple sclerosis
29 déc. 2022 12h09 HE
|
AB Science
PRESS RELEASE AB SCIENCE HAS RECEIVED APPROVAL FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) TO INITIATE THE CONFIRMATORY PHASE 3 STUDY WITH MASITINIB IN THE TREATMENT OF PROGRESSIVE MULTIPLE...
Sordoni Golf Outing Raises $40,000 for the Linda E. Cardinale Multiple Sclerosis Center
13 oct. 2022 11h30 HE
|
Sordoni Construction Co.
BEDMINSTER, N.J., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Sordoni Construction Co., a Bedminster-based construction management company, recently donated $40,000 to The Linda E. Cardinale Multiple...